Literature DB >> 10924273

Urinary lactate excretion to monitor the efficacy of treatment of type I glycogen storage disease.

T Hagen1, M S Korson, J I Wolfsdorf.   

Abstract

The purpose of this study was to investigate the usefulness of urinary lactate measurements to assess the adequacy of dietary treatment in patients with type I glycogen storage disease (GSD-I). We determined the correlation of urine and blood lactate concentrations in 21 GSD-I patients during 24-h admissions to the General Clinical Research Center (GCRC) during which hourly blood samples and aliquots of every void were obtained. In all but 1 patient, we found a good correlation between blood lactate concentrations and urinary lactate excretion. One patient did not excrete lactate in significant amounts despite elevated blood lactate concentrations. In 17 patients, the highest blood lactate concentrations occurred during the night. Markedly elevated nighttime average blood lactate concentrations above 3.5 mmol/l resulted in a urinary lactate concentration above the normal limit of 0.067 mmol/mmol creatinine in the first morning urine specimen. Mildly elevated nighttime blood lactate concentrations (between 2.2 and 3.5 mmol/l) led to urinary lactate concentrations that were either normal or moderately elevated. All patients with normal blood lactate concentrations during the night also had normal first morning urinary lactate concentrations. The degree of urinary lactate excretion in relation to blood lactate concentrations varied by individual. Urinary filter paper specimens, collected at home during the night and in the morning and mailed to the laboratory, were used to monitor the dietary compliance of 5 GSD-I patients at home over a period of 6 to 9 weeks prior to their GCRC admissions. These data suggested variable degrees of dietary control. In conclusion, the urinary lactate concentration is a useful parameter to monitor therapy of GSD-I patients at home. To be interpretable, the baseline urinary lactate concentration in relation to the blood lactate concentration has to be determined. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10924273     DOI: 10.1006/mgme.2000.3013

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  7 in total

1.  Clinical evaluation of a portable lactate meter in type I glycogen storage disease.

Authors:  A C Saunders; H A Feldman; C E Correia; D A Weinstein
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

2.  Continuous glucose monitoring in children with glycogen storage disease type I.

Authors:  E Hershkovitz; A Rachmel; H Ben-Zaken; M Phillip
Journal:  J Inherit Metab Dis       Date:  2001-12       Impact factor: 4.982

Review 3.  Paper-based assays for urine analysis.

Authors:  Eric Lepowsky; Fariba Ghaderinezhad; Stephanie Knowlton; Savas Tasoglu
Journal:  Biomicrofluidics       Date:  2017-10-17       Impact factor: 2.800

4.  Use of modified cornstarch therapy to extend fasting in glycogen storage disease types Ia and Ib.

Authors:  Catherine E Correia; Kaustuv Bhattacharya; Philip J Lee; Jonathan J Shuster; Douglas W Theriaque; Meena N Shankar; G Peter A Smit; David A Weinstein
Journal:  Am J Clin Nutr       Date:  2008-11       Impact factor: 7.045

5.  Modification of microfluidic paper-based devices with silica nanoparticles.

Authors:  Elizabeth Evans; Ellen Flávia Moreira Gabriel; Tomás E Benavidez; Wendell Karlos Tomazelli Coltro; Carlos D Garcia
Journal:  Analyst       Date:  2014-11-07       Impact factor: 4.616

Review 6.  Non-Invasive Electrochemical Biosensors Operating in Human Physiological Fluids.

Authors:  Magnus Falk; Carolin Psotta; Stefan Cirovic; Sergey Shleev
Journal:  Sensors (Basel)       Date:  2020-11-07       Impact factor: 3.576

7.  Urine lactate concentration as a non-invasive screener for metabolic abnormalities: Findings in children with autism spectrum disorder and regression.

Authors:  Sofie Boterberg; Elise Vantroys; Boel De Paepe; Rudy Van Coster; Herbert Roeyers
Journal:  PLoS One       Date:  2022-09-09       Impact factor: 3.752

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.